abciximab
Modify Date: 2025-08-25 10:59:51
abciximab structure
|
Common Name | abciximab | ||
|---|---|---|---|---|
| CAS Number | 143653-53-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of abciximabAbciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors[1]. |
| Name | abciximab |
|---|---|
| Synonym | More Synonyms |
| Description | Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet αIIbβ3 integrin[2]. Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2]. |
| In Vivo | Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia[2]. Animal Model: Male Wistar rats weighing 200-250 g, balloon angioplasty model[2] Dosage: 0.25 mg/kg/day Administration: Intravenous injection, 28 days Result: Time-dependently inhibited both neointimal hyperplasia and lumen occlusion after angioplasty in carotid arteries of rats. Significantly reduced PDGF-BB expression in vessel lumens and neointimal smooth muscle cells after angioplasty. Suppressed the elevation of plasma TxB2 concentration. |
| References |
| No Any Chemical & Physical Properties |
| ABCIXIMAB |